Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 24Other hematologic neoplasm 13Gastrointestinal 5CNS 5Other solid neoplasm 3Breast 3Thoracic 2Sarcoma 2Plasma cell 2Gynecologic 2Myeloid 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Immunotherapy, Adoptive × Dermatologic × Clear all
NCT00324623 2012-11-20

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Centre Hospitalier Universitaire Vaudois

Phase 1 Completed
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡